Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexamethasone modulates CD2 expression

G Migliorati1, A Bartoli, G Nocentini

  • 1Department of Clinical Medicine, Pathology and Pharmacology, University of Perugia, Italy.

International Journal of Immunopharmacology
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accuracy and reliability of an augmented reality prototype for robot-assisted partial nephrectomy: a preclinical study with 3D-printed kidney phantoms (UroCCR 168).

Journal of robotic surgery·2026
Same author

Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkers.

NPJ precision oncology·2026
Same author

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.

ESMO open·2025
Same author

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response.

ESMO open·2025
Same author

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

ESMO open·2025
Same author

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.

ESMO open·2025
Same journal

Induction of surface antigen CD69 expression in T-lymphocytes following exposure to actinomycin D.

International journal of immunopharmacology·2003
Same journal

Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1alpha,25-dihydroxyvitamin D3.

International journal of immunopharmacology·2003
Same journal

Differential effect of a single high dose of the tricyclic antidepressant imipramine on interleukin-1beta and tumor necrosis factor-alpha secretion following an in vivo lipopolysaccharide challenge in rats.

International journal of immunopharmacology·2003
Same journal

Pharmacokinetic properties, induction of interferon, and efficacy of selected 5-halo-6-phenyl pyrimidinones, bropirimine analogues, in a model of severe experimental autoimmune encephalomyelitis.

International journal of immunopharmacology·2003
Same journal

[3H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine.

International journal of immunopharmacology·2003
Same journal

Report of the second annual walker's cay colloqium on cancer vaccines and immunotherapy, March 8-11, 2000.

International journal of immunopharmacology·2001
See all related articles

Dexamethasone (DEX) increases CD2 molecule expression on T-cells by boosting mRNA levels. This glucocorticoid effect is transient and mediated by the glucocorticoid receptor (GCR).

Area of Science:

  • Immunology
  • Endocrinology
  • Molecular Biology

Background:

  • Glucocorticoid hormones (GCs) are known to modulate leukocyte activity.
  • CD2 is an adhesion molecule crucial for T-lymphocyte homing and activation.

Purpose of the Study:

  • To investigate the effect of dexamethasone (DEX) on CD2 expression in T-cells.
  • To elucidate the molecular mechanisms underlying DEX-induced CD2 modulation.

Main Methods:

  • Flow cytometry analysis to quantify CD2 expression.
  • Immunoprecipitation with anti-CD2 monoclonal antibodies.
  • Assessment of mRNA levels and inhibition studies with actinomycin-D (AD) and RU486.

Main Results:

  • In vitro treatment with DEX significantly augments CD2 expression in transformed T-cell lines.

Related Experiment Videos

  • This augmentation correlates with a rapid increase in CD2 mRNA levels.
  • The effect is transient, dose-dependent, mediated by the glucocorticoid receptor (GCR), and specific to GCs.

    • Conclusions:

    • Dexamethasone enhances CD2 expression on T-cells, likely contributing to GC-mediated effects on T-cell activity.
    • The mechanism involves increased CD2 mRNA synthesis via the GCR.
    • This modulation offers insights into the immunomodulatory roles of glucocorticoids.